340 related articles for article (PubMed ID: 10464225)
21. ucFabV Requires Functional Reductase Activity to Confer Reduced Triclosan Susceptibility in Escherichia coli.
Fischer TL; White RJ; Mares KF; Molnau DE; Donato JJ
J Mol Microbiol Biotechnol; 2015; 25(6):394-402. PubMed ID: 26683704
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of triclosan inhibition of bacterial fatty acid synthesis.
Heath RJ; Rubin JR; Holland DR; Zhang E; Snow ME; Rock CO
J Biol Chem; 1999 Apr; 274(16):11110-4. PubMed ID: 10196195
[TBL] [Abstract][Full Text] [Related]
23. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus.
Fan F; Yan K; Wallis NG; Reed S; Moore TD; Rittenhouse SF; DeWolf WE; Huang J; McDevitt D; Miller WH; Seefeld MA; Newlander KA; Jakas DR; Head MS; Payne DJ
Antimicrob Agents Chemother; 2002 Nov; 46(11):3343-7. PubMed ID: 12384334
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs.
Sivaraman S; Zwahlen J; Bell AF; Hedstrom L; Tonge PJ
Biochemistry; 2003 Apr; 42(15):4406-13. PubMed ID: 12693936
[TBL] [Abstract][Full Text] [Related]
25. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis.
Heath RJ; Yu YT; Shapiro MA; Olson E; Rock CO
J Biol Chem; 1998 Nov; 273(46):30316-20. PubMed ID: 9804793
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
Sivaraman S; Sullivan TJ; Johnson F; Novichenok P; Cui G; Simmerling C; Tonge PJ
J Med Chem; 2004 Jan; 47(3):509-18. PubMed ID: 14736233
[TBL] [Abstract][Full Text] [Related]
27. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.
Lu H; Tonge PJ
Biochemistry; 2010 Feb; 49(6):1281-9. PubMed ID: 20055482
[TBL] [Abstract][Full Text] [Related]
28. Potent antimicrobial action of triclosan-lysozyme complex against skin pathogens mediated through drug-targeted delivery mechanism.
Hoq MI; Ibrahim HR
Eur J Pharm Sci; 2011 Jan; 42(1-2):130-7. PubMed ID: 21078387
[TBL] [Abstract][Full Text] [Related]
29. Characterization of protein-ligand binding interactions of enoyl-ACP reductase (FabI) by native MS reveals allosteric effects of coenzymes and the inhibitor triclosan.
Joyner PM; Tran DP; Zenaidee MA; Loo JA
Protein Sci; 2022 Mar; 31(3):568-579. PubMed ID: 34882866
[TBL] [Abstract][Full Text] [Related]
30. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA).
Brenwald NP; Fraise AP
J Hosp Infect; 2003 Oct; 55(2):141-4. PubMed ID: 14529640
[TBL] [Abstract][Full Text] [Related]
31. cDNA cloning and expression of Brassica napus enoyl-acyl carrier protein reductase in Escherichia coli.
Kater MM; Koningstein GM; Nijkamp HJ; Stuitje AR
Plant Mol Biol; 1991 Oct; 17(4):895-909. PubMed ID: 1912503
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and Structural Basis of Triclosan Resistance in a Novel Enoyl-Acyl Carrier Protein Reductase.
Khan R; Zeb A; Roy N; Thapa Magar R; Kim HJ; Lee KW; Lee SW
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891603
[TBL] [Abstract][Full Text] [Related]
33. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
Yao J; Maxwell JB; Rock CO
J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
[TBL] [Abstract][Full Text] [Related]
34. Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan.
Kapoor M; Reddy CC; Krishnasastry MV; Surolia N; Surolia A
Biochem J; 2004 Aug; 381(Pt 3):719-24. PubMed ID: 15086316
[TBL] [Abstract][Full Text] [Related]
35. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei.
Liu N; Cummings JE; England K; Slayden RA; Tonge PJ
J Antimicrob Chemother; 2011 Mar; 66(3):564-73. PubMed ID: 21393229
[TBL] [Abstract][Full Text] [Related]
36. An Efficient and Economical Assay to Screen for Triclosan Binding to FabI.
Demissie RD; Kabre P; Tuntland ML; Fung LW
J Biomol Screen; 2016 Apr; 21(4):391-8. PubMed ID: 26538431
[TBL] [Abstract][Full Text] [Related]
37. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors.
Kapoor M; Dar MJ; Surolia A; Surolia N
Biochem Biophys Res Commun; 2001 Dec; 289(4):832-7. PubMed ID: 11735121
[TBL] [Abstract][Full Text] [Related]
38. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum.
Surolia N; Surolia A
Nat Med; 2001 Feb; 7(2):167-73. PubMed ID: 11175846
[TBL] [Abstract][Full Text] [Related]
39. Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.
Vick JE; Clomburg JM; Blankschien MD; Chou A; Kim S; Gonzalez R
Appl Environ Microbiol; 2015 Feb; 81(4):1406-16. PubMed ID: 25527535
[TBL] [Abstract][Full Text] [Related]
40. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase.
Perozzo R; Kuo M; Sidhu Ab; Valiyaveettil JT; Bittman R; Jacobs WR; Fidock DA; Sacchettini JC
J Biol Chem; 2002 Apr; 277(15):13106-14. PubMed ID: 11792710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
